ME02847B - Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala - Google Patents
Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanalaInfo
- Publication number
- ME02847B ME02847B MEP-2017-235A MEP23517A ME02847B ME 02847 B ME02847 B ME 02847B ME P23517 A MEP23517 A ME P23517A ME 02847 B ME02847 B ME 02847B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- heteroaryl
- independently selected
- halo
- cycloalkyl
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- -1 -O-CHF2 Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pyridine Compounds (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (1)
1. Jednjenje sa formulom III:gde:R1 je aril ili heteroaril odabran iz grupe koja se sastoji od:gde pomenuti aril ili heteroaril su supstituisani sa jednim dva, ili tri supstituenta nezavisno odabranih iz grupe koja se sastoji od hidroksi!, halo, -NO2, CN, -SF5, -Si(CH3)3 -O-CF3, -O-R20, -S-R20, -C(O)-R20, C(O)OH,-N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22,-N(R20)-S(=O)2-R26, -S(=O)2- R20, -S(=O)2-N(R20)(R22), C1-C3 alkoksi, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heteroaril, i heterociklil;gde pomenuti alkoksi, alkil, alkenil, alkinil, heteroaril, cikloalkil, ili heterociklil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksil, halo, -NO2 , -O-CF3, -O-CHF2, fenil, heterociklil, heteroaril, cikloalkil, -N(R 20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O-R20,ili gde R1 je supstituisan sa jednim, dva, ili tri supstituenta nezavisno odabranih odR2 je nezavisno odabran iz grupe koja se sastoji od vodonika, po izboru supstituisanog alkila, amino, po izboru supstituisanog alkoksi, -CF3, -O-CF3, -CN, i -N(R 20)C(O)-R22 ;R3 je nezavisno odabran iz grupe koja se sastoji od vodonika, alkila,- CF3, -halo, i -O-R4 je nezavisno odabran iz grupe koja se sastoji od vodonika, hidroksila, halo, C1-4 alkila, C1-C3 alkoksi, -R25-N(R20)(R22), -R25-O-R20, -R25-C(O)-O-R20, -R25-C(O)-N(R20)(R22),-R25-C(O)-O-N(R20)(R22), -R25-N(R20)-C(O)-R22, i -R25-O-C(O)-N(R20)(R22),gde pomenuti alkil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksil i halo,Q je odabran od kovalentne veze ili C2-4 alkinilena;Ra je vodonik, C1-15 alkil, C1-4 alkoksi, -C(O)-O-R26, -C(O)-N(R26)(R28), -N(R20)-S(=O)2-R20, cikloalkil, aril, heteroaril, i heterociklil, gde pomenuti alkil je po izboru supstituisan sa jedan, dva, ili tri supstituenta nezavisno odabranih od hidroksil, halo, -NO2, -O-CF3, -O-CHF2, cikloalkil, -CN, i C1-4 alkoksi; ipomenuti alkoksi, cikloalkil, aril, heterociklil, ili heteroaril su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, -NO2, -O-CF3, -O-CHF2, fenila, heterociklila, heteroarila, cikloalkila, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O-R20; iliRa je-Y-Z-R25-R23-R2o, gde,Y je kovalentna veza ili odabran od C1-C3 alkilena po izboru supstituisanog sa jedan ili dva C1-C3 alkila ili fluora grupe;Z je C2-4 alkinilen, -O-, -S-, -NR", -NR"-, -NR5'-C(O), -NR"-C(O)-NR5'- ili -C(O)-NR3-, gde svako R" i R5' je nezavisno vodonik ili C1-6 niži alkil; idalje gde pomenuti alkil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, -NO2, -O-CF3, -O-CHF2, fenila, heterociklila, heteroarila, cikloalkila, -N(R2O)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O- R2o ,iligde Ra je odabran iz grupe koja se sastoji odR20 i R22 su u svakom slučaju nezavisno odabrani iz grupe koja se sastoji od vodonika, C1-C15 alkila, C2-C15 alkenila, C2-C15 alkinila, cikloalkila, heterociklila, arila, i heteroarila,gde alkil, alkenil, alkinil, heterociklil, aril, i heteroaril su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, alkila, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, -CF3, -OCF3, arila, cikloalkila, i heteroarila; ili;kada R20 i R22 su vezani za zajednički atom azota R20 i R22 se mogu spojiti da formiraju heterociklični prsten koji je zatim po izboru supstituisan sa jedan, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, alkila, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, -CF3, i -OCF3, arila, i cikloalkila;R23 je kovalentna veza ili je odabrana iz grupe koja se sastoji od cikloalkilena, heterociklilena, arilena, i heteroarilena,gde cikloalkilen, heterociklilen, arilen, i heteroarilen su po izboru supstituisani sa jednim do tri supstituenta nezavisno odabranih od hidroksila, halo, alkil.a, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, - CF3, -OCF3, arila, cikloalkila, i heteroarila;R24 je u svakom slučaju nezavisno odabran od alkila i l i arila od kojih svaki može po izboru biti supstituisan sa 1, 2, ili 3 grupe nezavisno odabrane od hidroksi la, -OCF3, halo, C1-C3 alkoksi, -O-R20, ili alkila po izboru supstituisanog sa halo, -NO2, -CF3, -O-CF3, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, ili -O-R20 ;R25 je u svakom slučaju nezavisno kovalentna veza ili odabran od C1-C3 alkilena po izboru supstituisanog sa jednom ili dve C1 -C3 alkil grupe; iR26 i R28 su u svakom slučaju nezavisno odabrani od vodonika, alki la, ili cikloalkila, gde alkil i cikloalki l mogu dalje biti supstituisani sa od 1 do 3 supstituenta nezavisno odabranih od hidroksil, halo, C1 -4 alkoksi, -CF3, i -OCF3;ili njegove farmaceutski prihvatljive soli, estra, ili solvata,pod uslovima daa. kada Ra je -Y-Z-R25-R23-R20, Y nije kovalentna veza i Z je -0-, -S-, -C(O)-NR3-, -NR5 -C(O)-, ili NR"-, onda R25 ne može biti veza;b. kada Raje -Y-Z-R 25-R23-R20,Y je kovalentna veza i Z je -O-, -S-, ili NR"-, onda R25 je kovalentna veza i R23 nije cikloalkilen;c. kada Z je -NR 5'-C(O)-, onda Y nije kovalentna veza;d. R23 i R25 ne mogu oba biti kovalentne veze; ie. kada Q je veza, i R1 je heteroaril, onda R1 heteroaril možda neće dalje biti supstituisan sa fenilom; if. kada R2 je supstituisan alkil, onda Ra nije alkil, cikloalkil, ili heterociklil.
2. Jedinjenje patentnog zahteva 1 , gde Q je C2-4 alkinilen.
4. Jedinjenje patentnog zahteva 1, gde R1 je heteroaril.
8. Jedinjenje patentnog zahteva 1 , gde R1 je aril po izboru supstituisan sa halo, hidroksil, metoksi, etoksi, -OCF3, ili amino.
11. Jedinjenje bilo kog od patentnih zahteva l do l O za primenu u metodi za lečenje stanja bolesti kod sisara koje je olakšana tretmanom sa agensom koji je sposoban da smanji kasnu struju natrijuma.
12. Primena jedinjenja bilo kog od patentnih zahteva l do l O za pripremanje farmaceutske kompozicije za lečenje stanja bolesti kod sisara koje je olakšano tretmanom sa agensom koji je sposoban da smanji kasnu struju natrijuma.
13. Jedinjenje patentnog zahteva ll ili primena prema patentnom zahtevu 12, gde stanje bolesti je kardiovaskulama bolest odabrana od jedne ili više od atrijalnih i ventrikulamih aritmija, srčane insuficijencije (uključujući kongestivnu srčanu insuficijenciju, dijastolnu srčanu insuficijenciju, sistolnu srčanu insuficijenciju, akutnu srčanu insuficijenciju), Princmetalove (varijantu) angine, stabilne i nestabilne angine, angine izazvane vežbanjem, kongestivne srčane bolesti, ishemije, rekurentne ishemije, reperfuzione povrede, infarktamiokarda, akutnog koronarnog sindroma, periferne arterijske bolesti, plućne hipertenzije, intermitentne klaudikacije; ili stanje bolesti je dijabetes ili dijabetička periferna neuropatija; ili stanje bolesti rezultira u jednom ili više od neuropatskog bola, epilepsije, napada ili paralize.
14. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv ekscipijens i terapijski efikasnu količinujedinjenja bilo kog od patentnih zahteva l do 10 ili farmaceutski prihvaljivu so, estar ili hidrat togjedinjenja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22886409P | 2009-07-27 | 2009-07-27 | |
| US36003710P | 2010-06-30 | 2010-06-30 | |
| EP10737724.4A EP2464645B1 (en) | 2009-07-27 | 2010-07-26 | Fused heterocyclic compounds as ion channel modulators |
| PCT/US2010/043264 WO2011014462A1 (en) | 2009-07-27 | 2010-07-26 | Fused heterocyclic compounds as ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02847B true ME02847B (me) | 2018-01-20 |
Family
ID=42751632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-235A ME02847B (me) | 2009-07-27 | 2010-07-26 | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8952034B2 (me) |
| EP (1) | EP2464645B1 (me) |
| CN (1) | CN102725290B (me) |
| AR (1) | AR077598A1 (me) |
| AU (1) | AU2010276537B2 (me) |
| CA (1) | CA2774715C (me) |
| CY (1) | CY1119584T1 (me) |
| DK (1) | DK2464645T3 (me) |
| EA (1) | EA025824B1 (me) |
| ES (1) | ES2642586T3 (me) |
| HR (1) | HRP20171454T8 (me) |
| HU (1) | HUE034911T2 (me) |
| LT (1) | LT2464645T (me) |
| ME (1) | ME02847B (me) |
| NZ (1) | NZ598942A (me) |
| PL (1) | PL2464645T3 (me) |
| PT (1) | PT2464645T (me) |
| RS (1) | RS56410B1 (me) |
| SI (1) | SI2464645T1 (me) |
| SM (1) | SMT201700456T1 (me) |
| TW (2) | TWI490217B (me) |
| UY (1) | UY32805A (me) |
| WO (1) | WO2011014462A1 (me) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02847B (me) | 2009-07-27 | 2018-01-20 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| NO3175985T3 (me) | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| AU2012310168B2 (en) | 2011-09-15 | 2015-07-16 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| CA2849505A1 (en) * | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| WO2013045519A1 (en) | 2011-09-27 | 2013-04-04 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| GB201321745D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201604466RA (en) * | 2013-12-20 | 2016-07-28 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| CA2881544A1 (en) * | 2014-02-13 | 2015-08-13 | Anna Chiu | Solid forms of a late sodium current inhibitor |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| BR112019010880A2 (pt) * | 2016-11-28 | 2019-10-01 | Praxis Precision Medicines, Inc. | compostos e seus métodos de uso |
| WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN117756800A (zh) | 2018-05-30 | 2024-03-26 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| EA202092908A1 (ru) * | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| CN114980899A (zh) * | 2019-11-26 | 2022-08-30 | 普拉西斯精密医药公司 | 离子通道调节剂 |
| AU2020392128A1 (en) | 2019-11-27 | 2022-06-09 | Praxis Precision Medicines, Inc. | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators |
| CN115768757B (zh) * | 2019-12-19 | 2025-07-11 | 美利坚合众国,由健康及人类服务部部长代表 | Cd206调节剂及其用途和制备方法 |
| KR20250005348A (ko) * | 2022-04-26 | 2025-01-09 | 프락시스 프리시젼 메디신즈, 인크. | 신경 장애의 치료 |
Family Cites Families (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL128591C (me) * | 1965-07-02 | |||
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) * | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| DE69219354T2 (de) | 1991-05-10 | 1997-10-23 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| EP0593603B1 (en) | 1991-06-28 | 2002-11-20 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5939412A (en) | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5663166A (en) | 1991-10-18 | 1997-09-02 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| CA2300906A1 (en) | 1997-09-08 | 1999-03-18 | Unilever Plc | Method for enhancing the activity of an enzyme |
| US6579875B1 (en) * | 1998-01-21 | 2003-06-17 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
| EP1054877A1 (en) | 1998-02-11 | 2000-11-29 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| HUP0101280A3 (en) | 1998-02-18 | 2003-02-28 | Neurosearch As | Positive ampa receptor modulator compounds and their use |
| EP1087968A1 (en) * | 1998-06-16 | 2001-04-04 | MERCK SHARP & DOHME LTD. | Triazolo-pyridine derivatives as ligands for gaba receptors |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000068203A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| CN1382205A (zh) | 1999-08-27 | 2002-11-27 | 宝洁公司 | 快速作用的制剂组分、使用该制剂组分的组合物和洗衣方法 |
| WO2001016278A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Color safe laundry methods employing zwitterionic formulation components |
| WO2001016276A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Stability enhancing formulation components, compositions and laundry methods employing same |
| CZ2002720A3 (cs) | 1999-08-27 | 2002-09-11 | The Procter & Gamble Company | Složky zesilující bělení, prostředky a způsoby praní s využitím složek zesilujících bělení |
| CN100383230C (zh) | 1999-08-27 | 2008-04-23 | 宝洁公司 | 配制组分的可控制利用,使用该组分的组合物和洗衣方法 |
| BR0013647A (pt) | 1999-08-27 | 2002-05-07 | Procter & Gamble | Métodos de lavagem com proteção á cor empregando componentes de formulação catiÈnicas |
| CA2382023A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Stable formulation components, compositions and laundry methods employing same |
| US6469020B2 (en) | 2000-05-15 | 2002-10-22 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives |
| BR0112883A (pt) | 2000-08-01 | 2003-06-24 | Ono Pharmaceutical Co | Composto de derivado de 3,4-diidroisoquinolina e um agente farmacêutico compreendendo o mesmo como ingrediente ativo |
| AU2001288485A1 (en) | 2000-08-29 | 2002-03-13 | Balekudru Devadas | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| EP1354602B1 (en) | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
| DE60210755T2 (de) | 2001-03-09 | 2006-11-16 | Pfizer Products Inc., Groton | Triazolopyridine als entzündungshemmende mittel |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| BR0313384A (pt) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
| US7005523B2 (en) * | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| AU2003262073A1 (en) | 2002-09-20 | 2004-04-08 | Tsumura And Co. | Antitussives |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| WO2004037997A2 (en) | 2002-10-22 | 2004-05-06 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| EP1562925B1 (en) | 2002-11-07 | 2007-01-03 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EA200501117A1 (ru) | 2003-01-13 | 2006-02-24 | Кортекс Фармасеутикалс, Инк. | Способ лечения снижения когнитивной способности вследствие лишения сна и стресса |
| AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| WO2004094371A2 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2004096767A1 (en) | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| AR045445A1 (es) * | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| BRPI0417674A (pt) | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| AU2005272627A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| WO2006023750A2 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CA2579850A1 (en) | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Tricyclic anilide spirohydantoin cgrp receptor antagonists |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| PL2444079T3 (pl) | 2005-05-17 | 2017-07-31 | Sarcode Bioscience Inc. | Kompozycje i sposoby leczenia chorób oczu |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7495111B2 (en) | 2005-06-17 | 2009-02-24 | Wyeth | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| GB0516963D0 (en) * | 2005-08-18 | 2005-09-28 | Carbonite Corp | Liquid dispensers |
| EP1932549B1 (en) | 2005-08-26 | 2016-12-28 | AMNOS Co., Ltd. | Dried amnion and method for drying treatment of amnion |
| WO2007038138A2 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| MX2008004024A (es) | 2005-09-23 | 2009-02-27 | Schering Corp | Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos. |
| WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| JP2009515976A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロラクタム二環式ｃｇｒｐ受容体アンタゴニスト |
| AU2006316627A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| BRPI0619966A2 (pt) * | 2005-12-16 | 2011-10-25 | Alcon Inc | controle de pressão intra-ocular usando agentes de modulação de alk5 |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| US8097617B2 (en) * | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
| WO2007146284A2 (en) * | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
| WO2008005338A1 (en) | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| WO2008007661A1 (en) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| US20100035756A1 (en) | 2006-07-12 | 2010-02-11 | Syngenta Limited | Triazolophyridine derivatives as herbicides |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CN101553224A (zh) * | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| DK2343286T3 (en) | 2006-10-28 | 2015-04-13 | Methylgene Inc | Dibenzo [b, f] [1,4] oxazepine derivatives as inhibitors of histone deacetylase |
| WO2008053913A1 (en) | 2006-11-02 | 2008-05-08 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| EP2101775A1 (en) | 2006-12-21 | 2009-09-23 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| CL2008000252A1 (es) | 2007-01-29 | 2008-03-14 | Xenon Pharmaceuticals Inc | Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir |
| JP2010520237A (ja) | 2007-02-28 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ナトリウムチャネル遮断薬としての置換ベンゾジアゼピノン、ベンゾオキサアゼピノン及びベンゾチアゼピノン |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| WO2009026444A1 (en) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| WO2009036144A1 (en) | 2007-09-12 | 2009-03-19 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| PL2231662T3 (pl) | 2007-12-19 | 2011-11-30 | Genentech Inc | 8-anilinoimidazopirydyny oraz ich zastosowanie jako czynników przeciwnowotworowych i/lub przeciwzapalnych |
| WO2009089027A1 (en) * | 2008-01-09 | 2009-07-16 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health | Phosphodiesterase inhibitors |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| EP2307027A4 (en) | 2008-07-11 | 2012-08-15 | Neumedics | TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES |
| EP2314583B1 (en) | 2008-08-12 | 2015-02-25 | Nippon Soda Co., Ltd. | Nitrogenated heterocyclic derivative, and agricultural or horticultural bactericidal agent |
| CA2734449A1 (en) | 2008-08-18 | 2010-02-25 | Ube Industries, Ltd. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
| US20100056536A1 (en) | 2008-09-04 | 2010-03-04 | Charles Antzelevitch | Method of treating atrial fibrillation |
| US20100113461A1 (en) | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
| WO2010056527A2 (en) | 2008-10-30 | 2010-05-20 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| EP2373645A4 (en) | 2008-12-08 | 2012-05-02 | Sirtris Pharmaceuticals Inc | ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
| US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| FR2943342B1 (fr) | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| ME02847B (me) | 2009-07-27 | 2018-01-20 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
| RU2654068C1 (ru) | 2009-09-28 | 2018-05-16 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3 и способы применения |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| US20140378436A9 (en) | 2010-11-24 | 2014-12-25 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (me) | 2011-07-01 | 2018-04-28 | ||
| WO2013112932A1 (en) | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2010
- 2010-07-26 ME MEP-2017-235A patent/ME02847B/me unknown
- 2010-07-26 CN CN201080043104.0A patent/CN102725290B/zh active Active
- 2010-07-26 PL PL10737724T patent/PL2464645T3/pl unknown
- 2010-07-26 LT LTEP10737724.4T patent/LT2464645T/lt unknown
- 2010-07-26 SM SM20170456T patent/SMT201700456T1/it unknown
- 2010-07-26 AU AU2010276537A patent/AU2010276537B2/en active Active
- 2010-07-26 HR HRP20171454TT patent/HRP20171454T8/hr unknown
- 2010-07-26 NZ NZ598942A patent/NZ598942A/en active Application Filing
- 2010-07-26 SI SI201031540T patent/SI2464645T1/sl unknown
- 2010-07-26 EA EA201290121A patent/EA025824B1/ru unknown
- 2010-07-26 EP EP10737724.4A patent/EP2464645B1/en active Active
- 2010-07-26 PT PT107377244T patent/PT2464645T/pt unknown
- 2010-07-26 CA CA2774715A patent/CA2774715C/en active Active
- 2010-07-26 US US12/843,702 patent/US8952034B2/en active Active
- 2010-07-26 HU HUE10737724A patent/HUE034911T2/hu unknown
- 2010-07-26 RS RS20170990A patent/RS56410B1/sr unknown
- 2010-07-26 DK DK10737724.4T patent/DK2464645T3/en active
- 2010-07-26 ES ES10737724.4T patent/ES2642586T3/es active Active
- 2010-07-26 WO PCT/US2010/043264 patent/WO2011014462A1/en not_active Ceased
- 2010-07-27 TW TW099124710A patent/TWI490217B/zh active
- 2010-07-27 TW TW104112388A patent/TWI542587B/zh active
- 2010-07-27 AR ARP100102716A patent/AR077598A1/es not_active Application Discontinuation
- 2010-07-27 UY UY0001032805A patent/UY32805A/es not_active Application Discontinuation
-
2014
- 2014-05-09 US US14/274,422 patent/US9371329B2/en active Active
-
2017
- 2017-10-04 CY CY20171101028T patent/CY1119584T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02847B (me) | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala | |
| JP2008523069A5 (me) | ||
| HRP20171122T1 (hr) | Novi makrociklusi kao inhibitori faktora xia | |
| SI2966067T1 (en) | OKSAZEPINI AS ION CHANNEL MODULATORS | |
| JP2006143746A5 (me) | ||
| JP2009527501A5 (me) | ||
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| JP2007523139A5 (me) | ||
| JP2010529033A5 (me) | ||
| JP2010510232A5 (me) | ||
| RU2003131687A (ru) | Камзилат амлодипина, способ его получения и фармацевтическая композиция на его основе | |
| CN108675937A (zh) | 一种α-氨基酸的合成方法 | |
| RU2010147865A (ru) | Производные бензимидазола | |
| SU906346A3 (ru) | Фунгицидное средство | |
| CN100579970C (zh) | 杀菌剂异噻唑啉酮的制备方法 | |
| JP2011500796A (ja) | 新規前駆体 | |
| JP2006517932A5 (me) | ||
| ES2923932T3 (es) | Un procedimiento mejorado para la preparación de rivaroxabán que implica un intermedio novedoso | |
| KR101643285B1 (ko) | （하이드록시알킬）피롤 유도체의 회전장애이성질체 | |
| FI59802B (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla nya substituerade 2-fenylamino-imidazoliner-(2) och deras syraadditionssalter | |
| JP2013536823A5 (me) | ||
| JP2009520018A5 (me) | ||
| CN108191746B (zh) | 一种羟基吡啶酮类化合物及其制备方法与应用 | |
| JP2007532700A5 (me) | ||
| FI71738B (fi) | Foerfarande foer framstaellning av 5,6,7,7a-tetrahydro-4h-tien(3,2-c)pyridin-2-onderivat |